Bridges S L
Division of Clinical Immunology and Rheumatology, 415 Lyons-Harrison Research Building, University of Alabama at Birmingham, Birmingham, AL 35294-0007, USA.
Curr Rheumatol Rep. 1999 Dec;1(2):164-71. doi: 10.1007/s11926-999-0014-4.
There has been an explosion of knowledge of genetic variations among different populations and the influence of genetics on complex diseases such as rheumatoid arthritis (RA). Although class II major histocompatibility complex (MHC) alleles are important contributors, there are likely multiple other genes that modulate the disease phenotype. Genetic markers may allow prediction of response to particular treatments. Given the recent approval of tumor necrosis factors (TNF) inhibitors and the large number of biologic agents currently undergoing clinical trials, pharmacogenetic markers may prove to be clinically useful.
不同人群间基因变异的知识以及遗传学对类风湿性关节炎(RA)等复杂疾病的影响迅速增长。尽管II类主要组织相容性复合体(MHC)等位基因是重要因素,但可能还有多个其他基因调节疾病表型。基因标记物或许能够预测对特定治疗的反应。鉴于肿瘤坏死因子(TNF)抑制剂最近获批,以及目前大量生物制剂正在进行临床试验,药物遗传学标记物可能被证明具有临床实用性。